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Inhalation anesthetic isoflurane inhibits hypoxia pulmonary vasoconstriction (HPV), while dexmedetomidine (Dex) could reduce
the dose of isoflurane inhalation and potentiate HPV, but the mechanism is unclear. Inhibition of reactive oxygen species
(ROS) production can favor HPV during one-lung ventilation (OLV). Similarly, nitric oxide (NO), an important endothelium-
derived vasodilator in lung circulation, can decrease the regional pulmonary vascular resistance of ventilated lung and reduce
intrapulmonary shunting.We hypothesized that Dexmay augment HPV and improve oxygenation during OLV through inhibiting
oxidative stress and increasing NO release. Patients undergoing OLV during elective thoracic surgery were randomly allocated to
either isoflurane + saline (NISO, 𝑛 = 24) or isoflurane + dexmedetomidine (DISO, 𝑛 = 25) group. Anesthesia was maintained with
intravenous remifentanil and inhalational isoflurane (1.0–2.0%), with concomitant infusion of dexmedetomidine 0.7𝜇gkg−1h−1
in DISO and saline 0.25mL kg−1h−1 in NISO group. Hemodynamic variables or depth of anesthesia did not significantly differ
between groups. Administration of Dex significantly reduced Qs/Qt and increased PaO
2
after OLV, accompanied with reduced
lipid peroxidation product malondialdehyde and higher levels of SOD activity as well as serum NO (all 𝑃 < 0.05 DISO versus
NISO). In conclusion, reducing oxidative stress and increasing NO release during OLV may represent a mechanism whereby Dex
potentiates HPV.
1. Introduction
With the popularity of video-assisted thoracic surgery, the
requirement for one-lung ventilation (OLV) has been increas-
ing. OLV is used to provide a good surgical field and
protect normal lungs from hemorrhage or abscess caused
by affected lung [1]. However, OLV can induce ventilation-
perfusion mismatch and pulmonary arteriovenous shunt in
the nonventilated lung that can cause hypoxemia [2].Hypoxic
pulmonary vasoconstriction (HPV) is an important protec-
tive mechanism by which blood flow is diverted from the
nonventilated lung toward a better ventilated region, thereby
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maintaining adequate arterial oxygenation [3]. Inhalational
anesthetic sevoflurane and isoflurane have been shown to
inhibit HPV and thereby increase hypoxemia [4]. Dextral
dexmedetomidine (Dex) is a new highly selective alpha2-
adrenergic receptor agonist which has been increasingly used
both in the intensive care unit and also perioperatively as
an adjunct to general anesthesia. Dex has been shown to
reduce the dose of the inhalational and intravenous anes-
thetics [5, 6] and to reduce anti-inflammatory properties
against sepsis induced lung injury [7] and in bleeding-
induced multiple organ dysfunction syndrome in rats [8].
Our recent study showed that intravenous infusion of Dex
combined with inhalation of isoflurane potentiated HPV and
thereby improved oxygenation during OLV [9]. However, the
underlying mechanism remains to be elucidated.
Dex can induce vasoconstriction by activating alpha2-
adrenoreceptor at a dose dependent manner [10]. It was
reported that Dex even at a concentration 5 to 15 times lower
than the clinically recommended plasma target concentration
(0.4 to 1.2 ng/mL) could induce vasoconstriction [11]. Also,
Dex at the clinical concentration can decrease the redistribu-
tion of pulmonary blood flow from the ventilated to the non-
ventilated lung [9]. How did Dex maintain or augment the
small pulmonary arteries contraction in the nonventilated
lung and/or induce vasodilation in the ventilated lung? The
ventilated lung should have the same alpha2- adrenoreceptors
as the nonventilated lung in a specific person. This suggests
that Dex may have conferred its effects through mechanisms
other than a direct vasoconstriction modulator by activation
of alpha2-adrenoceptor agonist.
Current evidence suggests that reactive oxygen species
(ROS) and oxidative stress play a fundamental role in
the regulation of HPV [12, 13]. Hypoxia is monitored by
the pulmonary arteries smooth muscle cells (PASMCs)
[14, 15]: during hypoxia, inhibition of ROS production
and changes in the ratios of cytosolic reducing cofactors
(GSH/GSSG, NADH/NAD+, and NADPH/NADP+) within
human PASMCs activate voltage-gated K+ channels in
PASMCs, resulting inmembrane depolarization and opening
of L-type Ca2+ channels, which increases intracellular Ca2+
concentration and then elicits compensatory pulmonary
artery constriction in hypoxic lung. Although inhibition of
ROS production favors HPV during acute hypoxia, clinical
studies found that during one-lung ventilation systematic
lipid peroxidation product malondialdehyde (MDA) level
was significantly increased which indicates increased oxida-
tive stress [16]. During one-lung ventilation, ROS can be
produced from multiple sources including mechanical ven-
tilation, surgical trauma, manipulated lung tissue, and hyper-
oxia in ventilated lung [17]. Hypoxia also damps the lev-
els of endogenous antioxidant enzyme superoxide dismu-
tase (SOD) [18, 19], which plays an important role in
balancing ROS generation and the overall tissue antiox-
idant capacity. Therefore, decreased SOD activity aggra-
vates oxidative stress, which alleviates HPV effect. Stud-
ies found that Dex can decrease oxidative stress during
pneumoperitoneum and strengthen the antioxidant defense
system [20]. Whether Dex can inhibit oxidative stress during
one-lung ventilation and whereby potentiates HPV effect is
unclear.
Nitric oxide (NO) is an important endothelium-derived
relaxing factor in lung circulation [21], which is produced
mainly from human pulmonary endothelial cells (PAECs)
in the pulmonary circulation by endothelial nitric oxide
synthase (eNOS). Studies found that inhalation of nitric oxide
can decrease the regional pulmonary vascular resistance of
ventilated lung area, decrease intrapulmonary shunting, and
improve arterial oxygenation [22, 23]. However, Takemoto
et al. reported that chronic hypoxia is associated with a
decrease in eNOS mRNA and protein expression in human
PAECs [24]. Alpha2-adrenergic receptor agonist can activate
NO production [25]. However, it is unknown whether Dex
can activate NO production and decrease intrapulmonary
shunting during one-lung ventilation in patients.
Therefore, the current study was designed to test the
hypothesis that Dex can inhibit oxidative stress and increase
NO production, whereby decreasing intrapulmonary shunt-
ing and improving arterial oxygenation in patients under
one-lung ventilation.
2. Methods
2.1. General Information. After approval of the institutional
ethical committee and written informed consent, 60 male
patients (40–60 years old, ASA I∼II, 50∼73 kg, 151∼175 cm
high) undergoing elective thoracic surgery were included
in the study. The clinical trial registration number is Chic
TROIR-15005784. Exclusion criteria were renal insufficiency,
liver dysfunction or ischemic or valvular heart disease, long-
term alcohol, opioid, or sedative hypnotic drug addiction and
dependency history, and neuropsychiatric diseases.
2.2. GroupDivision. All patients were randomly divided after
induction of general anaesthesia into two groups, intravenous
infusion of the Dex combined with isoflurane inhalation
(DISO group) and the intravenous infusion of normal saline
with isoflurane inhalation (ISO group), 30 patients in each
group. Both the patients and the anaesthesiologists were
blinded to the identity of the study drug (Dex or saline
placebo). Study drug (Dex) or placebo was prepared in a
50mL syringe without identification marked by specialized
staff, who does not take part in the process of anaesthesia and
the research.
2.3. Anaesthesia. Routine monitoring was established on all
patients including ECG, noninvasive blood pressure (NIBP),
and SPO
2
. Central vena catheterization, radial artery can-
nulation and module, and electrodes monitor for bispectral
index (BIS, Aspect Medical Systems) were also performed
in all patients. Anaesthesia was induced with intravenous
midazolam 2mg, fentanyl 4 ug/kg, propofol 2mg/kg, and
vecuronium 0.1mg/kg. A left-side double-lumen tube was
inserted and correct position was assured by auscultation and
by fiberoptic bronchoscopy before and after the patient was in
the lateral decubitus position. Intermittent positive pressure
ventilation (IPPV), mechanical ventilation, was used during
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one-lung ventilationwith tide volume (TV) 8mL/kg, respira-
tory rate (RR) 12 bpm, I : E = 1 : 2, FiO2 100%. After bronchial
intubation was positioned, patients in DISO group received
intravenous infusion of Dex (D-dexmedetomidine liquid,
Jiangsu Hengrui Medicine Co., Ltd., production, 100 ug/mL,
diluted with normal saline to 50mL) at 1.0 ug⋅kg−1⋅h−1 over
10 minutes, which was then reduced to 0.7 ug⋅kg−1⋅h−1 and
maintained throughout the study; patients in NISO group
were given intravenous infusion of 0.25mL⋅kg−1⋅h−1 saline,
and it was reduced to 0.18mL⋅kg−1⋅h−1 10 minutes later.
During maintenance of anesthesia, all patients were given
isoflurane 1.0 to 2.0%, intravenous infusion of remifentanil
0.1∼0.2 ug⋅kg−1⋅min−1, and rocuronium to maintain the BIS
between 40 to 60. Supplemental vasoactive drugs were
used to maintain hemodynamic stability, and the doses of
vasoactive drugs (atropine, ephedrine, and urapidil) used in
two groups were recorded.
2.4. Monitoring. Pulmonary function tests and arterial blood
gas analysis for all patients were performed before operation.
Arterial blood gases were drawn; central venous blood gas,
heart rate (HR), mean artery blood pressure (MAP), BIS
values, and intrapulmonary shunt according to the formula
Qs/Qt = [(Cc󸀠O2 aCaO2)/(Cc󸀠O2 aCvO2)]× 100% [26] were
recorded at 15 minutes during two-lung ventilation (TLV)
(TLV-15) and after 10, 20, 30, and 40min of OLV (OLV-10,
OLV-20, OLV-30, and OLV-40). Drager PM8030 was used to
measure the concentrations of isoflurane in the inhalation gas
(FiIso) and in the exhaled gas (EEIso).
2.5. Plasma SOD Activity and MDA Level. Blood sample was
collected at TLV-15 and OLV-10, OLV-20, OLV-30, and OLV-
40 minutes, respectively, and then plasma was separated by
centrifugation. Plasma SOD activity and MDA level were
measured by using specific reagents according to the proto-
cols provided by the manufacturer (Nanjing, Jiancheng Bio-
engineering Institute, China) as described [27, 28], in which
the xanthine oxidase method was used for the detection
of SOD activity while the thiobarbituric acid was used as
substrate for the detection of MDA [29].
2.6. Serum NO Concentration. Blood sample was collected at
TLV-15 and OLV-30 minutes, respectively, and then serum
was separated by centrifugation. Total NO concentration was
determined using an indirect method based on measure-
ment of nitrite concentration in serum according to Griess’s
method [30].
2.7. Statistical Analysis. The data were expressed as mean ±
standard deviation (𝑥 ± 𝑠). SPSS 13.0 statistical software was
used for analysis. The data that meet the analysis of variance
between groups comparison were analyzed by ANOVA;
pairwise comparison between groups was analyzed by SNK
test; one-lung ventilation blood gas analysis of data over time
was analyzed by repeated measures analysis of variance. A 𝑃
value less than 0.05 was considered statistically significantly
different.
Table 1: General characteristics and preoperative data.
DISO group NISO group
(𝑛 = 25) (𝑛 = 24)
Age (yr) 55 ± 12 56 ± 11
Gender (M/F) 17/8 16/8
Weight (kg) 61 ± 12 60 ± 14
Height (cm) 167 ± 5 165 ± 7
ASA physical status (I/II) 3/22 2/22
Preoperative blood gas
pH 7.42 ± 0.02 7.41 ± 0.03
PaO2 (mmHg) 79.7 ± 13.7 79.5 ± 14.1
PaCO2 (mmHg) 35.5 ± 3.7 34.9 ± 4.1
Hb (g/L) 119.5 ± 13.8 120.5 ± 12.5
Preoperative pulmonary function
FEV1 (%) 79 ± 17 81 ± 16
FVC (%) 86 ± 14 87 ± 11
FEV1/FVC (%) 83 ± 13 80 ± 10
FEV1: forced expiratory volume in one second; FVC: forced vital capacity;
Hb: hemoglobin. There is no statistic difference between groups.
3. Results
60 patients were enrolled in the study. 11 patients were
excluded from analysis (six in NISO and five in DISO group):
in group NISO, 3 patients had BIS value over the range while
another 3 cases had SpO2 less than 90% during one-lung
ventilation; in group DISO, 2 cases had BIS value over the
range and 3 cases had SpO2 less than 90%. Therefore, data
from 49 patients were statistically analyzed in this study: 25
in group DISO and 24 in group NISO.
Patients’ characteristics are presented in Table 1. There
were no differences among groups regarding age, weight,
height, ASA physical status, preoperative blood gas, and
preoperative pulmonary function.
As shown in Table 2, the values for pH, Hb, PaCO
2
,
SaO
2
, and ScvO
2
did not differ significantly between groups.
Initiation of OLV caused a significant decrease in PaO
2
during conversion from TLV to OLV in both groups and
PaO
2
reached its lowest value at OLV-30min. The decrease
in PaO
2
in group DISO was less severe as compared to NISO
during OLV (𝑃 < 0.05). However, there was no hypoxemia
(too low PaO
2
) recorded in both groups. On changing from
TLV to OLV, Qs/Qt% increased significantly in both groups
and peaked at OLV-30min, but the increase of Qs/Qt% in
group DISO was less severe as compared with group NISO
(𝑃 < 0.05, Table 2). Heart rate was significantly slower in
group DISO than that in group NISO (𝑃 < 0.05). However,
MAP and the use of vasoactive drugs were not significantly
different between the two groups (𝑃 > 0.05) (Table 2).
BIS values were similar throughout the studied period in
each group and between the two groups (Figure 1). FETIso
was significantly lower in group DISO throughout the study
as compared with group NISO (𝑃 < 0.05, Figure 2).
The plasma MDA level was about 10% higher in group
NISO than in group DISO at TLV-15min but it was not
statistically different (𝑃 > 0.05, Table 3). On changing from
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Table 2: Perioperative time-course changes of blood gas variables in DISO group (𝑛 = 25) and NISO group (𝑛 = 24) (𝑥 ± 𝑠).
Parameters Group TLV-15min OLV-10min OLV-20min OLV-30min OLV-40min
pH DISO 7.37 ± 0.04 7.38 ± 0.03 7.39 ± 0.04 7.40 ± 0.03 7.39 ± 0.04
NISO 7.37 ± 0.04 7.38 ± 0.03 7.39 ± 0.04 7.40 ± 0.03 7.39 ± 0.04
Hb (mg/L) DISO 118.5 ± 10.7 116.9 ± 12.5 117.5 ± 11.6 116.1 ± 14.2 115.3 ± 12.5
NISO 117.4 ± 12.4 117.0 ± 12.3 116.9 ± 14.3 115.9 ± 12.7 115.1 ± 13.4
Qs/Qt (%) DISO 11.5 ± 1.8 23.5 ± 2.9
ab 25.3 ± 2.3ab 27.1 ± 2.1ab 23.5 ± 2.2ab
NISO 12.0 ± 1.1 28.1 ± 2.5a 30.1 ± 2.0a 31.9 ± 1.9a 27.7 ± 2.0a
PaCO2 (mmHg)
DISO 34.8 ± 3.2 35.0 ± 3.1 35.1 ± 3.9 35.3 ± 4.1 35.1 ± 3.3
NISO 35.2 ± 3.1 35.7 ± 4.5 36.0 ± 3.7 35.7 ± 4.0 35.5 ± 4.2
SaO2 (%)
DISO 99.7 ± 0.1 99.0 ± 1.2 98.7 ± 0.3 98.4 ± 0.8 99.3 ± 0.5
NISO 99.7 ± 0.4 98.9 ± 0.7 98.4 ± 1.1 97.5 ± 1.5 99.2 ± 0.6
ScvO2 (%)
DISO 84.9 ± 9.1 84.5 ± 8.5 83.5 ± 6.9 82.2 ± 9.2 84.4 ± 5.9
NISO 84.5 ± 8.5 83.6 ± 7.1 81.7 ± 7.3 80.7 ± 9.4 82.7 ± 5.5
HR (beats/min) DISO 66.3 ± 9.2
b 65.5 ± 13.1b 67.5 ± 12.1b 68.7 ± 11.2b 67.6 ± 11.3b
NISO 77.5 ± 10.5 78.2 ± 12.8 78.7 ± 13.3 81.5 ± 14.1 78.4 ± 14.3
MAP (mmHg) DISO 78.9 ± 17.2 77.2 ± 12.5 76.1 ± 10.5 75.0 ± 16.2 76.6 ± 13.4
NISO 81.1 ± 15.7 79.1 ± 14.2 79.1 ± 14.7 77.5 ± 17.1 77.9 ± 15.3
PaO2 (mmHg)
DISO 457.5 ± 85.2 258.6 ± 68.6ab 198.5 ± 68.3ab 185.6 ± 73.2ab 209.6 ± 85.1ab
NISO 461.5 ± 87.5 223.5 ± 89.7a 165.2 ± 75.3a 151.3 ± 68.5a 171.6 ± 88.9a
a
𝑃 < 0.05 versus TLV-15min; b𝑃 < 0.05 versus NISO group.
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Figure 1: Perioperative time-course alterations of the bispectral
index (BIS) in DISO group and NISO group. The values were
measured as follows: 15min after two-lung ventilation (TLV-15),
10min after one-lung ventilation (OLV-10min), 20min after one-
lung ventilation (OLV-20min), 30min after one-lung ventilation
(OLV-30min), and 40min after one-lung ventilation (OLV-40min).
Data are presented as median (interquartile range).
TLV to OLV, the MDA level significantly increased further
in group NISO at OLV-30min (𝑃 < 0.05 versus TLV-15 and
versus DISO, Table 3), while MDA level did not significantly
increase in group DISO. Concomitant with the change of
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Figure 2: Perioperative time-course alterations of the end-
expiratory isoflurane concentration (EEIso) in DISO group and
NISO group. The values were measured as follows: 15min after
two-lung ventilation (TLV-15), 10min after one-lung ventilation
(OLV-10min), 20min after one-lung ventilation (OLV-20min),
30min after one-lung ventilation (OLV-30min), and 40min after
one-lung ventilation (OLV-40min). Data are presented as median
(interquartile range). ∗𝑃 < 0.05 intergroup comparison between
group DISO and group NISO.
MDA level, plasma SOD activity was significantly decreased
in group NISO at OLV-30min, which was remarkably lower
than that in group DISO (𝑃 < 0.05, Table 3), while there was
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Table 3: Changes in MDA level, SOD activity, and NO concentra-
tion in DISO group and NISO group (𝑥 ± 𝑠).
Group TLV-15min OLV-30min
MDA (umol/L) DISO (𝑛 = 25) 16.9 ± 1.7 17.5 ± 1.2
b
NISO (𝑛 = 24) 18.3 ± 1.7 21.0 ± 1.7a
SOD (ug/mL) DISO (𝑛 = 25) 1.9 ± 0.2 1.8 ± 0.3
b
NISO (𝑛 = 24) 1.9 ± 0.1 1.6 ± 0.2a
NO (ug/mL) DISO (𝑛 = 25) 1.9 ± 0.3 2.3 ± 0.3
a;b
NISO (𝑛 = 24) 1.9 ± 0.4 1.8 ± 0.1
a
𝑃 < 0.05 versus TLV-15min; b𝑃 < 0.05 versus NISO group.
no significant change in SOD activity in group DISO after
OLV.
We have observed the changes of Qs/Qt% and PaO
2
at 5 different time points from TLV-15min to OLV-40min
and found that, on changing from TLV to OLV, Qs/Qt%
increased significantly in both groups and peaked at OLV-
30min while PaO
2
reached its lowest value at OLV-30min
in both groups.These results suggested that the time point of
OLV-30min may be the key moment for NO releasing, so we
detected serum NO at the time point of OLV-30. There was
no significant difference in serumNO concentration between
two groups at TLV-15min. After conversion from TLV to
OLV-30min, the serum NO concentration was significantly
increased in group DISO (𝑃 < 0.05, Table 3), but it did not
change significantly in group NISO (𝑃 > 0.05, Table 3), and
the values of NO content at OLV-30min was significantly
higher in DISO than in NISO group.
4. Discussion
The use of intravenous infusion Dex combined inhalation
isoflurane in comparison with isoflurane alone can attenuate
the increase in shunt fraction and improve PaO2 in patients
undergoingOLV, but themechanism is unclear. In the current
study, we further revealed that plasmaMDA level remarkably
increased and SOD activity decreased in isoflurane group
accompanied with decreased NO concentration, while Dex-
isoflurane combination significantly decreased MAD level,
maintained SOD activity, and increased serum NO content
during OLV. The results support our hypothesis that Dex at
clinical dose combined with isoflurane can inhibit oxidative
stress and increase NO release compared with volatile anes-
thetics alone, whereby reducing shunt fraction and improving
oxygenation during one-lung ventilation.
The effect of DEX on HPV during OLV is likely dose
dependent. Kernan et al. recently reported that Dex adminis-
tered at a loading dose of 0.3 𝜇g/kg and an infusion rate of
0.3 𝜇g/kg/h did not affect HPV and oxygenation, although
the PaO2/FiO2 ratio in patients receiving Dex was relatively
higher [31]. However, in our previous [9] and current study,
Dex at a higher loading dose of 1 𝜇g/kg and an infusion of
0.7 𝜇g/kg/h, combined isoflurane, significantly limited the
increase in pulmonary shunt and the decrease in PaO2
in one-lung ventilated patients, compared with isoflurane
alone group. In the current study, DEX-isoflurane treatment
decreased plasma MDA content and kept SOD activity, an
indication of attenuation of oxidative stress and improvement
in the endogenous antioxidative capacity. Furthermore, Dex-
isoflurane treatment increase serum NO content, an impor-
tant endothelium-derived vasodilation factor. These results
suggested that DEX should be provided at a dose sufficient
to prevent oxidative stress.
ROS are important messengers produced in response to
changes in oxygen tension and contribute to the regulation
of acute HPV during hypoxia [12, 13]. Mehta et al. have
shown that under sustained hypoxic conditions (1–4 hours),
ROS production was decreased in nonventilation lung [14].
Consistent with Cheng et al. [16], in current study we found
that plasma MDA levels were significantly increased and
important antioxidant enzyme SOD activity was decreased
in patients during one-lung ventilation (OLV), accompanied
with increased shunt fraction and decreased PaO2, which
indicates that the increased oxidative stress may impair the
protective effect of HPV. Yamaguchi et al. found that, in
the presence of high level of ROS and reduced endogenous
SOD, HPVwas considerably suppressed in the isolated rabbit
lung but was restored after adding exogenous SOD in the
perfusate [32]. Together with above results, our findings that
Dex decreased MDA level and maintained SOD activity,
concomitant with decreased shunt fraction and increased
PaO2, suggested that inhibition of oxidative stress and restore
antioxidant defense system may be important mechanisms
whereby DEX can augment HPV during one-lung ventila-
tion.
The decrease in shunt fraction in the Dex group occurred
in conjunction with increase in nitric oxide concentration in
the serum, which suggests that the changes in shunt fraction
may be particularly caused by increased nitric oxide, an
important endothelium-derived relaxing factor. Mam et al.
found that nitroprusside caused less relaxation in the pul-
monary arteries in hypoxic than in normoxic rats, suggesting
decreased responsiveness of vascular smooth muscle cells
(VSMCs) to vasodilators [33]. Hakim et al. found nitric oxide
did not affect pulmonary vasoconstriction in hypoxia rat lung
[34]. Therefore, we postulated that increased serum nitric
oxide mainly affects the arteriovenous in the ventilated lung.
It has been reported that inhalation of nitric oxide (iNO)
decreases the regional pulmonary vascular resistance of
ventilated lung area, decreases intrapulmonary shunting, and
improves arterial oxygenation [23, 24], whileMinamishima et
al. [35] and Lang Jr. et al. [36] found that inhalation of nitric
oxide can increase serum nitrite and nitrate (NO), and NO
may be the most likely candidate for transducing the iNO
stimulus to the organs. Therefore, all above results suggested
that serumNOmay play an important role in improving arte-
rial oxygenation in ventilated lung. It is reported that Dex can
induce vasodilation through activation NO synthase (NOS)
[37, 38]. In the current study, Dex significantly increased
serum NO concentration, concomitant with decreased shunt
fraction and increased PaO2, which indicates that Dex may
have induced vasodilation in the ventilated lung by enhancing
NO release. In the current study isoflurane did not inhibit
NO activation after OLV, while studies found that volatile
anesthetics inhibit the NO-mediated relaxation in many
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vascular beds [39, 40], which may partly explain why volatile
anesthetics inhibit HPV.
In conclusion, intravenous infusion of the dexmedetomi-
dine along with isoflurane inhalation during OLV inhibits
oxidative stress and increases NO concentration, which may
represent a mechanism whereby dexmedetomidine attenu-
ates intrapulmonary shunt and improves arterial oxygenation
during one-lung ventilation in patients.
Conflict of Interests
The authors have no potential conflict of interests to declare.
Authors’ Contribution
Rui Xia and Jinjin Xu contribute equally to this study.
Acknowledgment
This study was supported by the NSFC grants (81301621).
References
[1] J. H. Campos, “Current techniques for perioperative lung
isolation in adults,” Anesthesiology, vol. 97, no. 5, pp. 1295–1301,
2002.
[2] W. Karzai and K. Schwarzkopf, “Hypoxemia during one-lung
ventilation: prediction, prevention, and treatment,” Anesthesi-
ology, vol. 110, no. 6, pp. 1402–1411, 2009.
[3] A. M. Evans and J. P. Ward, “Hypoxic pulmonary vasocon-
striction—invited article,” in Arterial Chemoreceptors, vol. 648
of Advances in Experimental Medicine and Biology, pp. 351–360,
2009.
[4] J. Y. Y. Wang, G. N. Russell, R. D. Page, M. Jackson, and S.
H. Pennefather, “Comparison of the effects of sevoflurane and
isoflurane on arterial oxygenation during one lung ventilation,”
British Journal of Anaesthesia, vol. 81, no. 6, pp. 850–853, 1998.
[5] R.Mariappan, H. Ashokkumar, and B. Kuppuswamy, “Compar-
ing the effects of oral clonidine premedication with intraopera-
tive dexmedetomidine infusion on anesthetic requirement and
recovery from anesthesia in patients undergoing major spine
surgery,” Journal of Neurosurgical Anesthesiology, vol. 26, no. 3,
pp. 192–197, 2014.
[6] J. A. Tan and K. M. Ho, “Use of dexmedetomidine as a sedative
and analgesic agent in critically ill adult patients: a meta-
analysis,” Intensive Care Medicine, vol. 36, no. 6, pp. 926–939,
2010.
[7] C. Zhou, Y.Wu,Y. Liu et al., “Dexmedetomidine inhibits inflam-
matory reaction in lung tissues of septic rats by suppressing
TLR4/NF-𝜅B pathway,” Mediators of Inflammation, vol. 2013,
Article ID 562154, 9 pages, 2013.
[8] L. Xianbao, Z. Hong, Z. Xu, Z. Chunfang, and C. Dunjin,
“Dexmedetomidine reduced cytokine release during postpar-
tum bleeding-inducedmultiple organ dysfunction syndrome in
rats,”Mediators of Inflammation, vol. 2013, Article ID 627831, 7
pages, 2013.
[9] R. Xia, H. Yin, Z. Y. Xia, Q. J. Mao, G. D. Chen, and
W. Xu, “Effect of intravenous infusion of dexmedetomidine
combined with inhalation of isoflurane on arterial oxygenation
and intrapulmonary shunt during single-lung ventilation,” Cell
Biochemistry and Biophysics, vol. 67, no. 3, pp. 1547–1550, 2013.
[10] E. S. W. Wong, R. Y. K. Man, P. M. Vanhoutte, and K. F. J. Ng,
“Dexmedetomidine induces both relaxations and contractions,
via different 𝛼
2
-adrenoceptor subtypes, in the isolated mesen-
teric artery and aorta of the rat,” Journal of Pharmacology and
Experimental Therapeutics, vol. 335, no. 3, pp. 659–664, 2010.
[11] P. Talke, E. Lobo, and R. Brown, “Systemically adminis-
tered alpha2-agonist-induced peripheral vasoconstriction in
humans,” Anesthesiology, vol. 99, no. 1, pp. 65–70, 2003.
[12] P. Ariyaratnam, M. Loubani, and A. H. Morice, “Hypoxic
pulmonary vasoconstriction in humans,” BioMed Research
International, vol. 2013, Article ID 623684, 8 pages, 2013.
[13] S. L. Archer, H. L. Reeve, E. Michelakis et al., “O
2
sensing is
preserved in mice lacking the gp91 phox subunit of NADPH
oxidase,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 96, no. 14, pp. 7944–7949, 1999.
[14] J. P. Mehta, J. L. Campian, J. Guardiola, J. A. Cabrera, E. K.Weir,
and J. W. Eaton, “Generation of oxidants by hypoxic human
pulmonary and coronary smooth-muscle cells,” Chest, vol. 133,
no. 6, pp. 1410–1414, 2008.
[15] S. A. Gupte and M. S. Wolin, “Oxidant and redox signaling in
vascular oxygen sensing: implications for systemic and pul-
monary hypertension,” Antioxidants and Redox Signaling, vol.
10, no. 6, pp. 1137–1152, 2008.
[16] Y.-D. Cheng, Y. Gao, H. Zhang, C.-J. Duan, and C.-F. Zhang,
“Effects of OLV preconditioning and postconditioning on lung
injury in thoracotomy,” Asian Journal of Surgery, vol. 37, no. 2,
pp. 80–85, 2014.
[17] P. Misthos, S. Katsaragakis, N. Milingos et al., “Postresectional
pulmonary oxidative stress in lung cancer patients. The role of
one-lung ventilation,” European Journal of Cardio-thoracic
Surgery, vol. 27, no. 3, pp. 379–383, 2005.
[18] B. Zhang, W. Niu, D. Xu et al., “Oxymatrine prevents hypoxia-
and monocrotaline-induced pulmonary hypertension in rats,”
Free Radical Biology and Medicine, vol. 69, pp. 198–207, 2014.
[19] O. F. Araneda and M. Tuesta, “Lung oxidative damage by
hypoxia,” Oxidative Medicine and Cellular Longevity, vol. 2012,
Article ID 856918, 18 pages, 2012.
[20] B. Cekic, S. Geze, G. Ozkan et al., “The effect of dexmedetomi-
dine on oxidative stress during pneumoperitoneum,” BioMed
Research International, vol. 2014, Article ID 760323, 5 pages,
2014.
[21] J. Subramani, M. D. M. Leo, K. Kathirvel et al., “Essential role
of nitric oxide in sepsis-induced impairment of endothelium-
derived hyperpolarizing factor-mediated relaxation in rat pul-
monary artery,” European Journal of Pharmacology, vol. 630, no.
1–3, pp. 84–91, 2010.
[22] H. Sahebjami, “Inhaled nitric oxide for the adult respiratory
distress syndrome,” The New England Journal of Medicine, vol.
329, no. 3, pp. 206–207, 1993.
[23] T. Grubb, J. H. M. Frendin, A. Edner, P. Funkquist, G. Heden-
stierna, and G. Nyman, “The effects of pulse-delivered inhaled
nitric oxide on arterial oxygenation, ventilation-perfusion dis-
tribution and plasma endothelin-1 concentration in laterally
recumbent isoflurane-anaesthetized horses,” Veterinary Anaes-
thesia and Analgesia, vol. 40, no. 6, pp. e19–e30, 2013.
[24] M. Takemoto, J. Sun, J. Hiroki, H. Shimokawa, and J. K.
Liao, “Rho-kinase mediates hypoxia-induced downregulation
of endothelial nitric oxide synthase,” Circulation, vol. 106, no.
1, pp. 57–62, 2002.
Mediators of Inflammation 7
[25] A. V. Maltsev, Y. M. Kokoz, E. V. Evdokimovskii, O. Y. Pimenov,
S. Reyes, andA. E. Alekseev, “Alpha-2 adrenoceptors and imida-
zoline receptors in cardiomyocytes mediate counterbalancing
effect of agmatine on NO synthesis and intracellular calcium
handling,” Journal of Molecular and Cellular Cardiology, vol. 68,
pp. 66–74, 2014.
[26] P. G. Roe and J. G. Jones, “Analysis of factors which affect
the relationship between inspired oxygen partial pressure and
arterial oxygen saturation,” British Journal of Anaesthesia, vol.
71, no. 4, pp. 488–494, 1993.
[27] W. Yao, G. Luo, G. Zhu et al., “Propofol activation of the Nrf2
pathway is associated with amelioration of acute lung injury
in a rat liver transplantation model,” Oxidative Medicine and
Cellular Longevity, vol. 2014, Article ID 258567, 9 pages, 2014.
[28] K. X. Liu, T. Rinne,W. He, F.Wang, and Z. Xia, “Propofol atten-
uates intestinal mucosa injury induced by intestinal ischemia-
reperfusion in the rat,” Canadian Journal of Anesthesia, vol. 54,
no. 5, pp. 366–374, 2007.
[29] S. Lei, W. Su, H. Liu et al., “Nitroglycerine-induced nitrate
tolerance compromises propofol protection of the endothelial
cells against TNF- 𝛼: the role of PKC- 𝛽
2
and nadph oxidase,”
Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID
678484, 9 pages, 2013.
[30] S. Lei, H. Li, J. Xu et al., “Hyperglycemia-induced protein
kinase C 𝛽2 activation induces diastolic cardiac dysfunction in
diabetic rats by impairing caveolin-3 expression and Akt/eNOS
signaling,” Diabetes, vol. 62, no. 7, pp. 2318–2328, 2013.
[31] S. Kernan, S. Rehman, T. Meyer, J. Bourbeau, N. Caron, and J.
D. Tobias, “Effects of dexmedetomidine on oxygenation during
one-lung ventilation for thoracic surgery in adults,” Journal of
Minimal Access Surgery, vol. 7, no. 4, pp. 227–231, 2011.
[32] K. Yamaguchi, K. Asano, T. Takasugi et al., “Modulation of
hypoxic pulmonary vasoconstriction by antioxidant enzymes
in red blood cells,” American Journal of Respiratory and Critical
Care Medicine, vol. 153, no. 1, pp. 211–217, 1996.
[33] V. Mam, A. F. Tanbe, S. H. Vitali, E. Arons, H. A. Christou,
and R. A. Khalil, “Impaired vasoconstriction and nitric oxide-
mediated relaxation in pulmonary arteries of hypoxia- and
monocrotaline-induced pulmonary hypertensive rats,” Journal
of Pharmacology and Experimental Therapeutics, vol. 332, no. 2,
pp. 455–562, 2010.
[34] T. S. Hakim, A. Pedoto, D. Mangar, and E. M. Camporesi,
“Nitric oxide plays a minimal role in hypoxic pulmonary
vasoconstriction in isolated rat lungs,” Respiratory Physiology
and Neurobiology, vol. 189, no. 1, pp. 93–98, 2013.
[35] S. Minamishima, K. Kida, K. Tokuda et al., “Inhaled nitric
oxide improves outcomes after successful cardiopulmonary
resuscitation in mice,” Circulation, vol. 124, no. 15, pp. 1645–
1653, 2011.
[36] J. D. Lang Jr., X. Teng, P. Chumley et al., “InhaledNO accelerates
restoration of liver function in adults following orthotopic liver
transplantation,” Journal of Clinical Investigation, vol. 117, no. 9,
pp. 2583–2591, 2007.
[37] J. Feldman, L. Fellmann, and P. Bousquet, “The central hypoten-
sive effect induced by 𝛼2-adrenergic receptor stimulation is
dependent on endothelial nitric oxide synthase,” Journal of
Hypertension, vol. 26, no. 5, pp. 1033–1036, 2008.
[38] A. Snapir, P. Talke, J. Posti, M. Huiku, E. Kentala, and
M. Scheinin, “Effects of nitric oxide synthase inhibition on
dexmedetomidine-induced vasoconstriction in healthy human
volunteers,” British Journal of Anaesthesia, vol. 102, no. 1, pp. 38–
46, 2009.
[39] Y. Vulliemoz, “The nitric oxide-cyclic 3󸀠,5󸀠-guanosine mono-
phosphate signal transduction pathway in the mechanism of
action of general anesthetics,” Toxicology Letters, vol. 100-101,
pp. 103–108, 1998.
[40] M. M. Arriero, L. Mun˜oz Alameda, A. Lo´pez-Farre´ et al.,
“Sevoflurane reduces endothelium-dependent vasorelaxation:
role of superoxide anion and endothelin,” Canadian Journal of
Anesthesia, vol. 49, no. 5, pp. 471–476, 2002.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
